Skip to main content

Table 1 Baseline characteristics of the cohort undergoing repeat TACE therapy

From: Prognostic role of alpha-fetoprotein in patients with hepatocellular carcinoma treated with repeat transarterial chemoembolisation

Baseline CharacteristicsOverall cohort n = 292
Age (years), mean, (SD)66 (10)
Male, n (%)254 (87)
Female, n(%)38 (13)
Ethnicity, n(%)
 Caucasian229 (78)
 Asian51 (17)
 Other12 (4)
Aetiology of Liver disease, n(%)
 HCV / HBV / ETOH120/58/122 (41/20/42)
 NAFLD / Haemochromatosis/ other67/12/14 (23/4/5)
BMI, mean (SD)26 (24-30)
Serum markers, median (IQR)
 AFP, ng/ml19 (5-175)
 ALT, U/L49 (32-78)
 Albumin, g/L34 (31-39)
 Bilirubin, μmol/L18 (12-27)
 INR1.1 (1.0-1.3)
 Creatinine, μmol/L75 (65-87)
 Na, mmol/L139 (137-140)
Liver function, n (%)
 Portal HTN / Ascites / HE253/39/16 (87/13/5)
 Child Pugh Score (A/B)178/88/(61/30)
 MELD score9 (7-11)
ECOG (0/1), n (%)127/165 (43/57)
Tumour Characteristics
 Tumour Nodules (1/2/3/>3), n (%)127/65/20/80 (43/22/7/27)
 Tumour Size, cm (median, IQR)3.3 ( 2.0-5.0)
 Macrovascular invasion, n (%)9 (3)
 Extrahepatic spread, n (%)5 (2)
BCLC stage (A/B/C), n (%)166/113/13 (57/39/4)
TACE treatments (2/3/>3) n (%)132/80/80 (45/27/27)
 Type (cTACE / DEB TACE / TAE)232/56/3 (79/19/1)
 Selectivity
  selective /superselective /non selective197/48/43 (67/16/15)
mRECIST Response, n (%) 
 Complete/Partial69/127 (24/43)
 Stable/Progressive26/22 (9/8)
Adverse Events, n (%)
 Death3 (1)
 Post TACE syndrome/Decompensation38/4 (13/1)
 Renal dysfunction/other3/12 (1/4)
Post TACE Treatment, n (%)59 (20)
 Resection/Ablation/PEI/SIRT8/33/11/9 (3/11/4/3)